about
Nanostructured Montmorillonite Clay for Controlling the Lipase-Mediated Digestion of Medium Chain Triglycerides.In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate.Distribution and Inhibition of Liposomes on Staphylococcus aureus and Pseudomonas aeruginosa Biofilm.Characterising lipid lipolysis and its implication in lipid-based formulation development.Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases.Novel Nanostructured Solid Materials for Modulating Oral Drug Delivery from Solid-State Lipid-Based Drug Delivery Systems.Controlled and Localized Nitric Oxide Precursor Delivery from Chitosan Gels to Staphylococcus aureus Biofilms.Taking the Silver Bullet Colloidal Silver Particles for the Topical Treatment of Biofilm-Related Infections.Oral nanomedicine approaches for the treatment of psychiatric illnesses.Efficacy of Poly-Lactic-Co-Glycolic Acid Micro- and Nanoparticles of Ciprofloxacin Against Bacterial Biofilms.Mind "De GaPP": in vitro efficacy of deferiprone and gallium-protoporphyrin against Staphylococcus aureus biofilms.Deferiprone and Gallium-Protoporphyrin Have the Capacity to Potentiate the Activity of Antibiotics in Staphylococcus aureus Small Colony Variants.A Topical Hydrogel with Deferiprone and Gallium-Protoporphyrin Targets Bacterial Iron Metabolism and Has Antibiofilm Activity.An in vivo safety and efficacy demonstration of a topical liposomal nitric oxide donor treatment for Staphylococcus aureus biofilm-associated rhinosinusitis.Supersaturated self-nanoemulsifying drug delivery systems (Super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs.Montmorillonite-lipid hybrid carriers for ionizable and neutral poorly water-soluble drugs: Formulation, characterization and in vitro lipolysis studies.Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysisIn vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS)Influence of Lipid Composition and Drug Load on the In Vitro Performance of Self-Nanoemulsifying Drug Delivery SystemsQuatsomes for the treatment of Staphylococcus aureus biofilmMontmorillonite and Laponite Clay Materials for the Solidification of Lipid-Based Formulations for the Basic Drug Blonanserin: In Vitro and in Vivo InvestigationsPoly(lactic-co-glycolic) Acid-Lipid Hybrid Microparticles Enhance the Intracellular Uptake and Antibacterial Activity of RifampicinSupersaturated Silica-Lipid Hybrid Oral Drug Delivery Systems: Balancing Drug Loading and In Vivo PerformanceEnhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybridsBacterial lipase triggers the release of antibiotics from digestible liquid crystal nanoparticlesInhibition of Staphylococcus aureus and Pseudomonas aeruginosa biofilms by quatsomes in low concentrationsEnzyme responsive copolymer micelles enhance the anti-biofilm efficacy of the antiseptic chlorhexidineOral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetateRifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections
P50
Q31147750-2099ACB5-037F-4789-B0FA-3B6266F1B2B0Q35136316-C99522F0-5D27-4DDF-8510-24CEDF358FB9Q35678511-EF0FEC0A-9901-4D4C-9442-532B1E02F4D2Q36331543-ADDBF994-7EAB-45A5-B8C3-54BC86892493Q38213809-C867A859-E907-437C-8ACF-1606AD74BB52Q38583850-9A1DBF33-AC94-42C7-ACBA-B360BE7EE22AQ38637176-FDDF9D14-D9B9-49C7-B801-41FA2CC8CF9CQ38672933-EE82A869-68C4-4C55-A23A-890E90E4600CQ38688882-5290ADA2-0E56-44D4-8076-D00F4646ACBFQ38831816-B8426078-6760-41A6-A66A-2C6772555DA3Q38902883-6AD18E78-218E-409D-8E88-A481A7268B96Q40142212-4D9B2930-5DA5-4E57-8C41-08781B1CF8B8Q40257070-84284143-A2A7-4E2F-B49A-14247B28A30EQ41112387-8CAFC7DB-64B4-4328-A871-3B39FEA86512Q42507291-EA3AC279-B7BC-4ABB-A04E-EBCDDBBAF0AAQ50650499-0536AAB9-AFA9-463C-B638-EBEE55340E9AQ50886983-60EF1C38-E81F-4411-996C-01536383CE33Q58199065-AFBD8493-53AF-484C-836B-10D28C2F729BQ58199076-6745E58B-F4B0-41CB-ADBC-C8E5A8CEC276Q59234623-E3CCC08E-3A8E-4186-9F21-F613EAF1DB53Q61970318-8C2EF309-A1DE-4399-9217-691A1728B39CQ61971647-AE9A24DD-32D4-4F22-864B-ABF7E3CFF644Q89511936-D9F4CCB8-2221-4F36-AC6D-1D791AD4977BQ90524376-E5E2328D-0257-485D-A33E-68DCA67602AFQ91824013-7C250A59-C76F-4274-B649-D7813F7ECBD8Q92280019-D36C9084-1421-4733-AAAA-7C63EB82DA4DQ92429344-418C2219-AFD6-4CE1-9E3E-8DF6692A0450Q92456118-C7AB5849-B313-49AC-9F23-FF0A6FCEDD9BQ92938721-F9373B3D-6FB6-40BA-BA2B-A1801C59B131Q93060445-23E1B0F8-F2F8-485E-8F08-333637F47D3E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicky Thomas
@ast
Nicky Thomas
@en
Nicky Thomas
@es
Nicky Thomas
@sl
type
label
Nicky Thomas
@ast
Nicky Thomas
@en
Nicky Thomas
@es
Nicky Thomas
@sl
prefLabel
Nicky Thomas
@ast
Nicky Thomas
@en
Nicky Thomas
@es
Nicky Thomas
@sl
P1053
D-1708-2016
P106
P1153
55154066000
P31
P3829
P496
0000-0001-8920-1391
P569
2000-01-01T00:00:00Z